News & Press Releases

Siegmund Gutman, Life Science Litigation Practice Chair and Patent Litigation Practice Co-Chair, was quoted by Bloomberg Law in an article focused on the biggest patent lawsuits surrounding pharmaceutical drugs and technologies that are set to go to trial in 2026.

Comments from White Collar Defense and Government Investigations Practice Co-chair Eóin Beirne and Litigation Associate Grady Campion were featured in a Law360 Healthcare Authority article previewing oral arguments in an Eleventh Circuit case challenging the constitutionality of the False Claims Act’s whistleblower provisions. This is a closely watched case that could ultimately head to the Supreme Court.

Joanne Hawana shared insights with Law360 Healthcare Authority about how drugmakers are responding to a series of pilot programs launched by the Food and Drug Administration. The new programs include an AI-assisted scientific review process and a program designed to accelerate the drug approval process, among other changes.

Boston Bar Journal published an article co-authored by Member Christopher Lisy and Associate Kayla LaRosa that offers guidance on understanding digital evidence and how to present it to fact-finders most effectively. The attorneys explain how the rise of AI-generated content is creating new challenges, including the prevalence of audio and video “deepfakes”.

Mitch Frazer was featured on the Toronto Metropolitan University’s website for his recent role as a speaker at the university’s “Law + Business: A Strategic Convergence”. The event highlighted a new admission stream created through a collaboration between the Ted Rogers MBA program and the Lincoln Alexander School of Law that allows students to earn a combined Juris Doctor and Master of Business Administration.

Endpoints News featured commentary from Mitchell Clough in an article about the impending deadline for two major drugmakers to appeal Inflation Reduction Act challenges to the US Supreme Court as the first set of negotiated Medicare drug prices is scheduled to take effect on January 1, 2026. While many experts doubt that the Supreme Court will intervene before the January deadline, companies may still hope for eventual rulings that could invalidate or reshape the program.